AGP Executive Report
Last update: 11 hours agoHealth Funding Scandal: Malta’s Passports Fund has stopped reimbursing a €10m health-centre upgrade programme after procurement and compliance concerns, refusing outstanding claims and letting the agreement lapse; the fallout follows findings against former Primary Health Care CEO Roseanne Camilleri and financial controller Alfred Farrugia over refurbishment irregularities at Birkirkara and Qormi. Rare Disease Drug Approval: The European Commission granted marketing authorisation under exceptional circumstances for NEZGLYAL® (leriglitazone), the first EU pharmacological treatment for childhood cerebral adrenoleukodystrophy (cALD) in boys aged 2–12 with Gd-negative brain lesions, with launches expected first in Germany. Rett Syndrome Sales Push: Neuren Pharmaceuticals is moving from European approval to first commercial sales for Daybue (trofinetide) for Rett syndrome, with the authorisation covering EU states including Liechtenstein and Norway. Cancer Treatment Update: EMA CHMP issued positive opinions for perioperative pembrolizumab-based regimens in muscle-invasive bladder cancer, including KEYTRUDA® plus Padcev® (and related formulations), now awaiting final European Commission decisions. Infectious Disease Trend: Switzerland reported 544 tuberculosis infections in 2025, the highest since 2018, driven largely by people of foreign origin, including teenagers and young adults.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
